Cloudbreak Pharma Inc.
2592.HKHKSEHealthcareBiotechnology
Latest quote
HK$1.22
+HK$0.02 · +1.67%
2592.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteCloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jinsong Ni
- Listed since
- Jul 2, 2025
- Employees
- 61
Market position
Day range
Current HK$1.22
52-week range
Current HK$1.22
- Open
- HK$1.20
- Previous close
- HK$1.20
- Volume
- 85.5K
- 0.18× average
- Average volume
- 474.3K
- Average daily volume
- Market cap
- 1.08B HKD
- Beta
- -1.76
- Market reference 1
- 50-day average
- HK$1.2351
- -1.22% below average
- 200-day average
- HK$2.5901
- -52.90% below average
2592.HK peers
Continue in GoAI
Research 2592.HKresearch.disclaimer